Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Filterwire EZ

This article was originally published in The Gray Sheet

Executive Summary

Domestic launch of next-generation embolic protection filter system for use in angioplasty and stent treatment of diseased saphenous vein grafts is announced Aug. 23 following FDA 510(k) clearance. Building on the first-generation Filterwire EX, launched in the U.S. in June 2003, the EZ debuted overseas last September featuring an updated "suspended loop" filter support design to enhance deliverability and effectiveness, Boston Scientific claims. The 510(k) was supported by the 90-patient BLAZE multi-center clinical registry. Separately, the firm reports FDA market go-ahead for its Peripheral Cutting Balloon angioplasty system. Featuring longitudinally mounted microsurgical blades, the device is intended to treat blocked hemodialysis access grafts in end-stage renal disease patients. The system requires less pressure and trauma than conventional angioplasty, the firm says...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel